Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (invirase) treatment

Journal of Medical Virology

Volumn 53, Issue 4, 1997, Pages 313-318

  Sarmati, L ^a   Nicastri, E ^a   El Sawaf, G ^a   Ventura, L ^a   Salanitro, A ^a   Ercoli, L ^a   Vella, S ^b   Andreoni, M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antiretroviral therapy; Disease progression; Humoral immunity; Neutralization

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NEUTRALIZING ANTIBODY; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG MIXTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LYMPHOCYTE COUNT; RANDOMIZED CONTROLLED TRIAL; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; RNA, VIRAL; SAQUINAVIR; TIME FACTORS; VIRAL LOAD; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031462952     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199712)53:4<313::AID-JMV1>3.0.CO;2-A     Document Type: Article

References (23)

1. Albert J, Abrahamson B, Nagy K, Aurelius E, Gaines H, Nystrom G and Feny EM (1990): Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variant which resist neutralization by autologous sera. AIDS 4:107-112.
2. Andreoni M, Sarmati L, Parisi SG, Ercoli L and Rocchi G (1992): Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma. Journal of Medical Virology 38:207-213.
3. Arendrup M, Nielsen C, Hansen JS, Pedersen C, Mathiesen L, and Nielsen JO (1992): Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. Journal of Acquired Immune Deficiency. Syndromes 5:303-307.
4. Arendrup M, Sonnerborg A, Svennerholm B, Akerblom L, Nielsen C, Clausen H, Olofsson S, Nielsen JO and Hansen JS (1993): Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. Journal of General Virology 74:855-863.
5. Connick E, Marr DG, Zhang X, Clark SJ, Saag MS, Schooley RT and Curiel TJ (1996): HIV-specific cellular and humoral responses in primary HIV infection. AIDS Research and Human Retroviruses 12:1129-1140.
6. Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer TS, Kuritzkes DR (1994): Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. Journal of Clinical Microbiology 32:2291-2294.
7. Montefiori DC, Zhou J, Barnes B, Lake D, Hersh EM, Masuho Y and Lefkowitz LB (1991): Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology 182:635-643.
8. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Mirales GD and Fauci AS (1996): Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. Journal of Infectious Diseases 173:60-67.
9. Mulder J, Mc Kinney N, Christopherson C, Sninsky J, Greenfield L and Kwok S (1994): Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNtAb in plasma: application to acute retroviral infection. Journal of Clinical Microbiology 32:292-300.
10. Nixon DF, Broliden K, Ogg G and Broliden PA (1992): Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 76:515-534.
11. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orestein JM, Fox C and Schrager LK (1995): Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. New England Journal of Medicine 332:209-216.
12. Poignard P, Klasse PJ and Sattentau QJ (1996): Antibody neutralization of HFV-1. Immunology Today 17 5:239-246.
13. Reitz MS, Wilson C, Naugle C, Gallo RC and Robert-Guroff M (1988): Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope. Cell 54:57-63.
14. Robert-Guroff M, Goedert JJ, Naugle CJ, Jennings AM, Blattner WA and Gallo RC (1988): Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: result of a 6 year prospective study. AIDS Research and Human Retroviruses 4:343-350.
15. Robert-Guroff M, Roilides E, Muldoon R, Venzon D, Husson R, Marhall D, Gallo RC and Pizzo PA (1993): Human immunodeficiency virus (HIV) type 1strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value. Journal of Infectious Diseases 167:538-546.
16. Sarmati L, Ercoli L, Parisi SG, Rocchi G, Giannini G, Galluzzo C, Vella S and Andreoni M (1994): High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment. Journal of AIDS 7:10-14.
17. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L and Feny EM (1993): Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. Journal of Infectious Diseases 168:207-210.
18. Schimidtmayerova H, Lackovicova M, Stankova M, Bruckoca M, Surovy I, Ujhelyi E, Fust G and Mayer V (1992): Virus neutralizing antibodies at different stages of the HIV disease: increased levels after azidothymidine treatment. Acta Virologica 36:157-165.
19. Schonning K, Nielsen C, Iversen J, Nielsen JO and Hansen JS (1995): Neutralizing antibodies in slowly progressing HIV-1 infection. Journal of Acquired Immune Deficiency. Syndromes 10:400-407.
20. Tsang ML, Evans LA, McQueen P, Hurren L, Byrne C, Penny R, Tindall B and Cooper D (1994): Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates after seroconversion. Journal of Infectious Diseases 170:1141-1147.
21. Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccaba rozzi S, Facey K, Duncan I, Boudes P and Bragman K (1996): A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antiviral Therapy 1:129-140.
22. Von Gegerfelt A, Albert J, Morfeldt-Manson L, Broliden K and Feny EM (1991): Isolate-specific neutralizing antibodies in patient with progressive HIV-1 related diseases. Virology 185:162-188.
23. Wainberg MA, Drodopoulos WC, Salomon H, Hsu M, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G and Prasad VR (1996): Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285.